The Effect of 3 Versus 6 Years of Zoledronic Acid Treatment of Osteoporosis: A Randomized Extension to the HORIZON-Pivotal Fracture Trial (PFT)

Black, D.; Reid, I.; Boonen, S.; Bucci-Rechtweg, C.; Cauley, J.; Cosman, F.; Cummings, S.; Hue, T.; Lippuner, K.; Lakatos, P.; Leung, P.; Man, Z.; Martinez, R.; Tan, M.; Ruzycky, M.; Su, Guoqin; Eastell, R.

doi:10.1002/jbmr.1494

Public

The Effect of 3 Versus 6 Years of Zoledronic Acid Treatment of Osteoporosis: A Randomized Extension to the HORIZON-Pivotal Fracture Trial (PFT)

Shared by NobleBlocks on Dec 8, 2011 • 12:00 AM UTC

Authors:

D. Black

I. Reid

S. Boonen

Abstract

Zoledronic acid 5 mg (ZOL) annually for 3 years reduces fracture risk in postmenopausal women with osteoporosis. To investigate long‐term effects of ZOL on bone mineral density (BMD) and fracture risk, the Health Outcomes and Reduced Incidence with Zoledronic acid Once Yearly–Pivotal Fracture Trial ...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!